Released Feb 24, 2026, before the open
10-K filed Feb 24, 2026, 55 days after period end · 0001193125-26-065189
Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$219.91M$219.91M derived+2.0% vs Q4 2024+6.9% vs Q3 2025
Net Income-$2.22M-$2.22M derivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$156,342,000+5.0%
Operating Incomederived$494,000N/M
Operating Cash Flowderived$27,697,000+16.7%
Free Cash Flowderived$16,820,000+19.6%
Margins · derived
Gross margin71.1%+2.1 pt vs Q4 2024
Operating margin0.2%+5.5 pt vs Q4 2024
Net margin-1.0%+12.5 pt vs Q4 2024
What the release said
The release
Same quarter
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Revenue | $219.91M | $215.66M | $200.42M | $122.23M |
| Net Income | -$2.22M | -$29.15M | -$22.17M | -$7.06M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Orthofix Medical Inc. · CIK 884624 · Engraved from SEC EDGAR